Strategic importance of research support through pathology

Area of Science:

• Drug Discovery and Development
• Toxicology and Pathology

Background:

• The rapid identification of new drug candidates necessitates efficient preclinical screening.
• Eliminating compounds with toxic liabilities early improves drug safety, reduces timelines, and increases success rates.
• Pharmaceutical companies increasingly utilize specialized pathology units to support research and development.

Purpose of the Study:

• To highlight the critical role of early pathology support in drug discovery.
• To outline current approaches for identifying toxic liabilities in drug candidates.
• To emphasize the importance of interdisciplinary collaboration and knowledge sharing.

Main Methods:

• High-throughput in vitro screening for toxicity prediction and mechanism identification.
• Target profiling to assess off-target receptor-ligand interactions.
• Acute in vivo studies to determine tolerability and target organs of toxicity.
• Application of advanced tools like genomics, proteomics, metabonomics, and engineered animal models.

Main Results:

• Early identification and elimination of toxic compounds streamline the drug development process.
• Integrated pathology support enables prediction of potential safety issues.
• Contemporary tools enhance the accuracy and efficiency of toxicity assessments.

Conclusions:

• Early pathology interaction with drug discovery teams is vital for identifying toxic liabilities.
• A combination of in vitro, in vivo, and omics approaches facilitates comprehensive safety evaluations.
• Active participation in knowledge sharing and education is essential for advancing discovery pathology and toxicology.